1. Small Leucine-Rich Proteoglycans (SLRPs) in the Retina
- Author
-
Shyam S. Chaurasia, Iris S. Kassem, Thomas B. Connor, Shermaine W. Y. Low, and Deborah M. Costakos
- Subjects
0301 basic medicine ,retina ,fibromodulin ,nyctalopin ,Decorin ,Lumican ,QH301-705.5 ,Review ,Biology ,Catalysis ,Inorganic Chemistry ,Extracellular matrix ,03 medical and health sciences ,opticin ,0302 clinical medicine ,Leucine ,medicine ,Animals ,Humans ,tsukushi ,Physical and Theoretical Chemistry ,Biology (General) ,Molecular Biology ,QD1-999 ,Spectroscopy ,decorin ,Small Leucine-Rich Proteoglycans ,Retina ,Extracellular Matrix Proteins ,Biglycan ,PRELP ,Organic Chemistry ,small leucine rich proteoglycans (SLRP) ,Fibrillogenesis ,lumican ,General Medicine ,biglycan ,osteoglycin/mimecan ,Computer Science Applications ,Cell biology ,Extracellular Matrix ,chondroadherin ,Chemistry ,030104 developmental biology ,medicine.anatomical_structure ,Chondroitin Sulfate Proteoglycans ,030221 ophthalmology & optometry ,Signal transduction ,Nyctalopin - Abstract
Retinal diseases such as age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and diabetic retinopathy (DR) are the leading causes of visual impairment worldwide. There is a critical need to understand the structural and cellular components that play a vital role in the pathophysiology of retinal diseases. One potential component is the family of structural proteins called small leucine-rich proteoglycans (SLRPs). SLRPs are crucial in many fundamental biological processes involved in the maintenance of retinal homeostasis. They are present within the extracellular matrix (ECM) of connective and vascular tissues and contribute to tissue organization and modulation of cell growth. They play a vital role in cell–matrix interactions in many upstream signaling pathways involved in fibrillogenesis and angiogenesis. In this comprehensive review, we describe the expression patterns and function of SLRPs in the retina, including Biglycan and Decorin from class I; Fibromodulin, Lumican, and a Proline/arginine-rich end leucine-rich repeat protein (PRELP) from class II; Opticin and Osteoglycin/Mimecan from class III; and Chondroadherin (CHAD), Tsukushi and Nyctalopin from class IV.
- Published
- 2021